Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Cencora, Inc. or Labcorp Holdings Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Cencora, Inc. and Labcorp Holdings Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Cencora, Inc. and Labcorp Holdings Inc.

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Latest Health Care Providers & Services and Cencora, Inc., Labcorp Holdings Inc. Stock News

As of July 31, 2026, Cencora, Inc. had a $60.6 billion market capitalization, compared to the Health Care Providers & Services median of $1.7 million. Cencora, Inc.’s stock is down 7.8% in 2026, up 0.5% in the previous five trading days and up 6.7% in the past year.

Currently, Cencora, Inc.’s price-earnings ratio is 23.9. Cencora, Inc.’s trailing 12-month revenue is $328.7 billion with a 0.8% net profit margin. Year-over-year quarterly sales growth most recently was 3.8%. Analysts expect adjusted earnings to reach $17.784 per share for the current fiscal year. Cencora, Inc. currently has a 0.8% dividend yield.

As of July 31, 2026, Labcorp Holdings Inc. had a $25.0 billion market cap, putting it in the 88th percentile of all stocks. Labcorp Holdings Inc.’s stock is up 23.2% in 2026, up 4.2% in the previous five trading days and up 17.16% in the past year.

Currently, Labcorp Holdings Inc.’s price-earnings ratio is 27.4. Labcorp Holdings Inc.’s trailing 12-month revenue is $14.1 billion with a 7.0% net profit margin. Year-over-year quarterly sales growth most recently was 5.8%. Analysts expect adjusted earnings to reach $18.335 per share for the current fiscal year. Labcorp Holdings Inc. currently has a 0.9% dividend yield.

How We Compare Cencora, Inc. and Labcorp Holdings Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Cencora, Inc. and Labcorp Holdings Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Cencora, Inc. and Labcorp Holdings Inc. Stock Value Grades

Company	Ticker	Value
Cencora, Inc.	COR	D
Labcorp Holdings Inc.	LH	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Cencora, Inc. has a Value Score of 37, which is Expensive. Labcorp Holdings Inc. has a Value Score of 40, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Cencora, Inc. or Labcorp Holdings Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Cencora, Inc. or Labcorp Holdings Inc. is the better investment when it comes to value.

Cencora, Inc. and Labcorp Holdings Inc. Growth Grades

Company	Ticker	Growth
Cencora, Inc.	COR	A
Labcorp Holdings Inc.	LH	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Cencora, Inc. has a Growth Score of 89, which is Very Strong. Labcorp Holdings Inc. has a Growth Score of 36, which is Weak.

The Growth Grade Winner: Cencora, Inc.

As you can clearly see from the Growth Grade breakdown above, Cencora, Inc. has a more attractive growth grade than Labcorp Holdings Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Cencora, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Cencora, Inc. and Labcorp Holdings Inc.’s Momentum Grades

Company	Ticker	Momentum
Cencora, Inc.	COR	C
Labcorp Holdings Inc.	LH	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Cencora, Inc. has a Momentum Score of 48, which is Average. Labcorp Holdings Inc. has a Momentum Score of 67, which is Strong.

The Momentum Grade Winner: Labcorp Holdings Inc.

As you can clearly see from the Momentum Grade breakdown above, Labcorp Holdings Inc. is considered to have stronger momentum compared to Cencora, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Labcorp Holdings Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Cencora, Inc. and Labcorp Holdings Inc. Grades

In addition to Momentum, Growth and Value, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Cencora, Inc. and Labcorp Holdings Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Cencora, Inc. or Labcorp Holdings Inc. Stock?

Overall, Cencora, Inc. stock has a Value Score of 37, Growth Score of 89 and Momentum Score of 48.

Labcorp Holdings Inc. stock has a Value Score of 40, Growth Score of 36 and Momentum Score of 67.

Comparing Cencora, Inc. and Labcorp Holdings Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.